# Intellia Therapeutics, Inc.: filings

NTLA · Nasdaq · CIK 1652130 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/ntla.md) · [Financials](/companies/ntla/financials.md) · [Filings](/companies/ntla/filings.md) · [Insiders](/companies/ntla/insiders.md)

## Reports and events: 206 filings

Newest first, by EDGAR acceptance time (Eastern). Filter with ?form= one of: `periodic`, `8-K`, `10-K`, `10-Q`, `4`, `proxy`, `13dg`, `all`, or any form this company filed (4 299, 8-K 137, 3 39, SC 13G/A 35, 10-Q 32, 424B5 15, S-8 12, 10-K 10, CORRESP 10, DEF 14A 10, SC 13G 10, 144 9, DEFA14A 8, SC 13D/A 8, UPLOAD 8, 4/A 6, CT ORDER 6, SCHEDULE 13G/A 6, ARS 4, EFFECT 4, S-1/A 4, DRS/A 3, S-3ASR 3, SCHEDULE 13G 3, PRE 14A 2, S-3 2, SC 13D 2, 10-K/A 1, 10-Q/A 1, 424B4 1, 8-A12B 1, CERTNAS 1, D 1, DRS 1, FWP 1, POS AM 1, POSASR 1, S-1 1, S-1MEF 1, S-3/A 1).

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-09-08 | 20:05 ET | [8-K](/filings/0001193125-26-385194.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-385194 |
| 2026-09-04 | 20:06 ET | [8-K](/filings/0001193125-26-383645.md) | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-383645 |
| 2026-08-06 | 20:05 ET | [10-Q](/filings/0001193125-26-337952.md) | Quarterly report, period 2026-06-30 | 0001193125-26-337952 |
| 2026-08-06 | 11:45 ET | [8-K](/filings/0001193125-26-336772.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-336772 |
| 2026-06-15 | 12:52 ET | [8-K](/filings/0001193125-26-270358.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-270358 |
| 2026-06-10 | 20:36 ET | [8-K](/filings/0001193125-26-265934.md) | 5.07 Shareholder vote results | 0001193125-26-265934 |
| 2026-05-11 | 11:49 ET | [10-Q](/filings/0001193125-26-215740.md) | Quarterly report, period 2026-03-31 | 0001193125-26-215740 |
| 2026-05-11 | 11:36 ET | [8-K](/filings/0001193125-26-215721.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-215721 |
| 2026-04-30 | 20:30 ET | [8-K](/filings/0001193125-26-197489.md) | 1.01 Entry into a material agreement; 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-197489 |
| 2026-04-30 | 20:10 ET | [DEF 14A](/filings/0001193125-26-197283.md) | Proxy statement, period 2026-06-09 | 0001193125-26-197283 |
| 2026-04-27 | 13:13 ET | [8-K](/filings/0001193125-26-179401.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-179401 |
| 2026-04-10 | 20:16 ET | [8-K](/filings/0001193125-26-151300.md) | 5.03 Amendment to articles or bylaws; 9.01 Financial statements and exhibits | 0001193125-26-151300 |
| 2026-03-02 | 13:16 ET | [8-K](/filings/0001193125-26-084309.md) | 1.01 Entry into a material agreement; 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-084309 |
| 2026-02-26 | 21:06 ET | [10-K](/filings/0001193125-26-076550.md) | Annual report, period 2025-12-31 | 0001193125-26-076550 |
| 2026-02-26 | 12:45 ET | [8-K](/filings/0001193125-26-073456.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-073456 |
| 2026-01-27 | 13:19 ET | [8-K](/filings/0001193125-26-023387.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-023387 |
| 2026-01-09 | 13:07 ET | [8-K](/filings/0001193125-26-008307.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-008307 |
| 2025-11-10 | 22:24 ET | [8-K](/filings/0001193125-25-274596.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-25-274596 |
| 2025-11-06 | 21:26 ET | [10-Q](/filings/0001193125-25-269680.md) | Quarterly report, period 2025-09-30 | 0001193125-25-269680 |
| 2025-11-06 | 21:06 ET | [8-K](/filings/0001193125-25-269479.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-25-269479 |
| 2025-10-29 | 20:22 ET | [8-K](/filings/0001193125-25-256378.md) | 8.01 Other events | 0001193125-25-256378 |
| 2025-10-27 | 12:01 ET | [8-K](/filings/0001193125-25-250757.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-25-250757 |
| 2025-09-25 | 20:19 ET | [8-K](/filings/0001193125-25-217484.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-25-217484 |
| 2025-08-07 | 20:06 ET | [10-Q](/filings/0000950170-25-104987.md) | Quarterly report, period 2025-06-30 | 0000950170-25-104987 |
| 2025-08-07 | 11:45 ET | [8-K](/filings/0000950170-25-104574.md) | 2.02 Results of operations; 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0000950170-25-104574 |
| 2025-06-16 | 11:00 ET | [8-K](/filings/0001193125-25-141087.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-25-141087 |
| 2025-06-12 | 20:31 ET | [8-K](/filings/0000950170-25-085479.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0000950170-25-085479 |
| 2025-05-28 | 20:38 ET | [8-K](/filings/0001193125-25-129524.md) | 7.01 Regulation FD disclosure; 8.01 Other events | 0001193125-25-129524 |
| 2025-05-19 | 10:21 ET | [8-K](/filings/0001193125-25-122076.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-25-122076 |
| 2025-05-08 | 20:05 ET | [10-Q](/filings/0000950170-25-066914.md) | Quarterly report, period 2025-03-31 | 0000950170-25-066914 |
| 2025-05-08 | 11:45 ET | [8-K](/filings/0000950170-25-066403.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-25-066403 |
| 2025-04-30 | 20:04 ET | [DEF 14A](/filings/0000950170-25-061023.md) | Proxy statement, period 2025-06-11 | 0000950170-25-061023 |
| 2025-04-07 | 10:05 ET | [8-K](/filings/0001193125-25-073904.md) | 5.03 Amendment to articles or bylaws; 9.01 Financial statements and exhibits | 0001193125-25-073904 |
| 2025-02-27 | 21:03 ET | [10-K](/filings/0000950170-25-029007.md) | Annual report, period 2024-12-31 | 0000950170-25-029007 |
| 2025-02-27 | 12:45 ET | [8-K](/filings/0000950170-25-028373.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-25-028373 |
| 2025-02-21 | 21:06 ET | [8-K](/filings/0001193125-25-031989.md) | 1.01 Entry into a material agreement; 2.03 New direct financial obligation | 0001193125-25-031989 |
| 2025-01-10 | 12:30 ET | [8-K](/filings/0001193125-25-004080.md) | 2.02 Results of operations; 2.05 Exit or disposal costs; 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-25-004080 |
| 2024-11-18 | 12:00 ET | [8-K](/filings/0001193125-24-260417.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-24-260417 |
| 2024-11-07 | 21:05 ET | [10-Q](/filings/0000950170-24-123276.md) | Quarterly report, period 2024-09-30 | 0000950170-24-123276 |
| 2024-11-07 | 12:45 ET | [8-K](/filings/0000950170-24-122810.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-122810 |
| 2024-10-25 | 20:59 ET | [8-K](/filings/0001193125-24-244201.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-24-244201 |
| 2024-08-08 | 20:06 ET | [10-Q](/filings/0000950170-24-093907.md) | Quarterly report, period 2024-06-30 | 0000950170-24-093907 |
| 2024-08-08 | 11:45 ET | [8-K](/filings/0000950170-24-093339.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-093339 |
| 2024-06-26 | 12:06 ET | [8-K](/filings/0001193125-24-168545.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-24-168545 |
| 2024-06-14 | 20:24 ET | [8-K](/filings/0000950170-24-073709.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000950170-24-073709 |
| 2024-06-13 | 20:59 ET | [8-K](/filings/0000950170-24-073116.md) | 5.03 Amendment to articles or bylaws; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0000950170-24-073116 |
| 2024-05-09 | 20:25 ET | [10-Q](/filings/0000950170-24-057046.md) | Quarterly report, period 2024-03-31 | 0000950170-24-057046 |
| 2024-05-09 | 11:40 ET | [8-K](/filings/0000950170-24-056286.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-056286 |
| 2024-04-29 | 20:16 ET | [DEF 14A](/filings/0000950170-24-049875.md) | Proxy statement, period 2024-06-12 | 0000950170-24-049875 |
| 2024-04-15 | 20:21 ET | [8-K](/filings/0000950170-24-044424.md) | 5.02 Departure or appointment of officers or directors | 0000950170-24-044424 |

Page 1 of 5. [Older](/companies/ntla/filings.md?page=2)
Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Oct 24, 2026, 15:07 ET. No prices; not investment advice.